3,5,7,3',4'-pentamethoxyflavone profile

3,5,7,3',4'-pentamethoxyflavone: causes relaxation of cavernosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	97332
CHEMBL ID	19032
SCHEMBL ID	2286327
MeSH ID	M0579747

Synonym
nsc618936
nsc-618936
pentamethylquercetin
SDCCGMLS-0066841.P001
smr000386999
MLS001048983
SPECTRUM_001718
SPECTRUM4_001790
SPECTRUM5_000439
BSPBIO_003338
4h-1-benzopyran-4-one,4-dimethoxyphenyl)-3,5,7-trimethoxy-
quercetin pentamethyl ether
3,4',5,7-pentamethoxyflavone
flavone,3',4',5,7-pentamethoxy-
nsc115922
1247-97-8
penta-o-methylquercitin
nsc-115922
quercetin-3,5,7,3',4'-pentamethylether
NCGC00095759-01
KBIO2_004766
KBIOGR_002341
KBIO2_002198
KBIOSS_002198
KBIO2_007334
KBIO3_002558
SPECTRUM3_001719
SPECTRUM2_001804
SPBIO_001787
SPECTRUM1600075
NCGC00178132-01
pentamethoxyquercetin
CHEMBL19032 ,
2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one
LMPK12112772
NCGC00095759-02
flavone, 3,3',4',5,7-pentamethoxy-
4h-1-benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-
v6j41k636o ,
quercetin-3,5,7,3',4'-pentamethyl ether
nsc 115922
unii-v6j41k636o
3,5,7,3',4'-pentamethyl ether
3,3',4',5,7-pentamethoxyflavone
HMS2268P21
CCG-38450
bdbm50404748
AB00637125-07
mfcd01004607
SCHEMBL2286327
2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-chromen-4-one
quercetin 3, 5, 7, 3', 4'-pentamethylether
ALGDHWVALRSLBT-UHFFFAOYSA-N
3,5,7,3',4'-pentamethoxyflavone
quercetin 3,5,7,3',4'-pentamethyl ether
DTXSID10154467
4h-1-benzopyran-4-one,2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-
AKOS030487720
SR-01000758970-2
sr-01000758970
2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-4h-1-benzopyran-4-one
2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-4h-chromen-4-one
STL512455
tum-8437
FT-0716793
MS-26004
quercetin 3,5,7,3,4-pentamethyl ether
3,5,7,3 inverted exclamation marka,4 inverted exclamation marka-pentamethoxyflavone
quercetin-3,5,7,3,4-pentamethylether
3,3`,4`,5,7-pentamethoxyflavone
E80655
CS-0135217
HY-N7690

Excerpt	Reference	Relevance
" Male rats were orally or intravenously administered a 250 mg/kg concentration of a KP extract, and blood samples were obtained at selected times to determine pharmacokinetic parameters of PMF, TMF, and DMF."	( Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. Jay, M; Mekjaruskul, C; Sripanidkulchai, B, 2012)	0.38
" Additional blood samples were collected at various times on the last day of treatment to evaluate the pharmacokinetic interactions."	( Pharmacokinetic interaction between Kaempferia parviflora extract and sildenafil in rats. Mekjaruskul, C; Sripanidkulchai, B, 2015)	0.42

Excerpt	Reference	Relevance
" The methoxyflavones showed low oral bioavailability of 1 to 4%."	( Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. Jay, M; Mekjaruskul, C; Sripanidkulchai, B, 2012)	0.38
" However, quercetin's low solubility and poor bioavailability have restricted its applicability; as a result, researchers have attempted to design and synthesize numerous novel quercetin derivatives using various methodologies in order to modify quercetin's constraints; the physico-chemical properties of quercetin's molecular scaffold make it appealing for drug development; low molecular mass and chemical groups are two of these characteristics."	( Quercetin derivatives: Drug design, development, and biological activities, a review. Alizadeh, SR; Ebrahimzadeh, MA, 2022)	0.72

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	10.0000	0.0040	23.8416	100.0000	AID485290
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	39.8107	0.0447	17.8581	100.0000	AID485341
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	33.5521	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	50.1187	5.6234	17.2929	31.6228	AID485281
acid sphingomyelinase	Homo sapiens (human)	Potency	25.1189	14.1254	24.0613	39.8107	AID504937
glp-1 receptor, partial	Homo sapiens (human)	Potency	12.5893	0.0184	6.8060	14.1254	AID624417
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	56.2341	0.1000	20.8793	79.4328	AID588456
ATAD5 protein, partial	Homo sapiens (human)	Potency	7.3048	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	20.7329	0.0008	11.3822	44.6684	AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	19.9526	0.0112	12.4002	100.0000	AID1030
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	20.4053	0.0398	16.7842	39.8107	AID1454; AID995
flap endonuclease 1	Homo sapiens (human)	Potency	79.4328	0.1337	25.4129	89.1251	AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	44.6684	0.4256	12.0591	28.1838	AID504891
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	1.2589	0.0316	10.2792	39.8107	AID884; AID885
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	25.1189	0.0041	9.9625	28.1838	AID2675
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	1.2589	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	23.4000	0.0002	2.3185	10.0000	AID768684
Multidrug resistance-associated protein 1	Homo sapiens (human)	IC50 (µMol)	26.3500	0.0015	3.7110	9.6600	AID768683
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Rattus norvegicus (Norway rat)	IC50 (µMol)	1,000.0000	0.1000	0.2000	0.3000	AID220159
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Rattus norvegicus (Norway rat)	IC50 (µMol)	1,000.0000	0.1000	0.2000	0.3000	AID220159
Phosphodiesterase	Rattus norvegicus (Norway rat)	IC50 (µMol)	1,000.0000	0.1000	0.2000	0.3000	AID220159
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	1.3510	0.0040	1.9666	10.0000	AID768689; AID768691
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
leukotriene metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
response to xenobiotic stimulus	Multidrug resistance-associated protein 1	Homo sapiens (human)
cobalamin transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid biosynthetic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to oxidative stress	Multidrug resistance-associated protein 1	Homo sapiens (human)
heme catabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
phospholipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
positive regulation of inflammatory response	Multidrug resistance-associated protein 1	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cell chemotaxis	Multidrug resistance-associated protein 1	Homo sapiens (human)
transepithelial transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cyclic nucleotide transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to amyloid-beta	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
lipid transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid biosynthetic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate metabolic process	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transmembrane transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transepithelial transport	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
renal urate salt excretion	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
export across plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
cellular detoxification	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type vitamin B12 transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basal plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
lateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
extracellular exosome	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (121)

Assay ID	Title	Year	Journal	Article
AID1223522	Cmax in Wistar rat brain at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596470	Effect on C/EBPbeta mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596452	Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in differentiated mouse 3T3L1 cells at 30 uM compound treated for 20 mins with insulin by liquid scintillation counting (Rvb = 100.0 %)	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID220005	Relative inhibition of cAMP and cGMP hydrolysis by cytosolic phosphodiesterase	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID666771	Inhibition of thrombin in New Zealand rabbit plasma assessed as fibrinogen level at 100 uM by coagulometry	2012	European journal of medicinal chemistry, Aug, Volume: 54	Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
AID596454	Effect on adiponectin mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596677	Induction of adiponectin protein secretion in mouse 3T3L1 cells at 30 uM on day 8 by ELISA relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596455	Effect on adiponectin mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596449	Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 30 uM by liquid scintillation counting (Rvb = 100.0 %)	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223521	Cmax in Wistar rat lung at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596457	Effect on PPARgamma2 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596671	Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 3 uM on day 8 relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223558	Elimination rate constant in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1705065	Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID596464	Effect on aP2 mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596469	Effect on C/EBPbeta mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223564	Volume of distribution in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID768691	Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID1223549	Drug metabolism in Wistar rat assessed as excretion of 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxy-4H-chromen-4-one in urine/feces at 750 mg/kg, po by LC-MS and LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID220001	Inhibition of rat brain cytosolic cAMP phosphodiesterase	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID220162	Inhibition of rat brain particulate cGMP phosphodiesterase	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID1223556	Half life in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223534	Drug metabolism in Wistar rat assessed as excretion of 3,5-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-methoxy-4H-chromen-4-one in feces at 750 mg/kg, po by LC-MS and LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223565	Absorption rate constant in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596669	Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 0.3 uM on day 8 relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596247	Effect on C/EBPdelta mRNA expression in mouse 3T3L1 adipocytes at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596673	Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 30 uM on day 8 relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596466	Effect on C/EBPalpha mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596468	Effect on C/EBPalpha mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596246	Effect on C/EBPdelta mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596672	Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 10 uM on day 8 relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223561	Clearance in Wistar rat at 250 mg/kg, iv by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1677633	Activation of CRE-mediated transcription in rat PC12D cells transfected with pCRE-firefly luciferase and pRL-null-renilla luciferase assessed as increase in CRE-driven firefly luciferase activity at 30 uM by dual luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Effect of methoxyflavones contained in Kaempferia parviflora on CRE-mediated transcription in PC12D cells.
AID768685	Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation at 10 uM preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay relative to control	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID1223557	Half life in Wistar rat at 250 mg/kg, iv by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223560	Clearance in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596679	Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 3 uM by liquid scintillation counting (Rvb = 100.0 %)	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596676	Induction of adiponectin protein secretion in mouse 3T3L1 cells at 10 uM on day 8 by ELISA relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223567	AUC (0.083 to 4 hrs) in Wistar rat liver at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596462	Effect on GlUT4 mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223527	Tmax in Wistar rat brain at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223519	Cmax in Wistar rat liver at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223563	Cmax in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID768683	Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID1223547	Drug excretion in Wistar rat feces at 750 mg/kg, po after 18 to 24 hrs by HPLC-UV analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1677634	Effect on transcription in rat PC12D cells transfected with pCRE-firefly luciferase and pRL-null-renilla luciferase assessed as renilla luciferase activity at 30 uM by dual luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Effect of methoxyflavones contained in Kaempferia parviflora on CRE-mediated transcription in PC12D cells.
AID596467	Effect on C/EBPalpha mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID666857	Reversal of BCRP-mediated drug resistant in human HEK293/R2 cells assessed as potentiation of topotecan-induced cytotoxicity at 1 uM after 5 days by MTS assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID1223524	Tmax in Wistar rat liver at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID666855	Cytotoxicity against mouse L929 cells after 5 days by MTS assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID596670	Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 1 uM on day 8 relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223555	AUC in Wistar rat at 250 mg/kg, iv by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223559	Elimination rate constant in Wistar rat at 250 mg/kg, iv by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1871969	Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins under dark condition	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Quercetin derivatives: Drug design, development, and biological activities, a review.
AID219998	Inhibition of rat brain cytosolic cAMP phosphodiesterase	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID220159	Inhibition of rat brain cytosolic cGMP phosphodiesterase	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID666768	Inhibition of thrombin in New Zealand rabbit plasma assessed as thrombin time at 100 uM after 3 mins by coagulometry	2012	European journal of medicinal chemistry, Aug, Volume: 54	Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
AID596451	Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in differentiated mouse 3T3L1 cells at 10 uM compound treated for 20 mins with insulin by liquid scintillation counting (Rvb = 100.0 %)	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596667	Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level on day 8	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223530	Drug excretion in Wistar rat urine at 750 mg/kg, po after 12 hrs by HPLC-UV analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223554	AUC in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596450	Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in differentiated mouse 3T3L1 cells at 3 uM compound treated for 20 mins with insulin by liquid scintillation counting (Rvb = 100.0 %)	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596674	Induction of adiponectin protein secretion in mouse 3T3L1 cells at 1 uM on day 8 by ELISA relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223566	Oral bioavailability in Wistar rat at 250 mg/kg by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223536	Drug excretion in Wistar rat feces at 750 mg/kg, po after up to 72 hrs by HPLC-UV analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID666770	Inhibition of thrombin in New Zealand rabbit plasma assessed as activated partial thromboplastin time at 100 uM after 3 mins by coagulometry	2012	European journal of medicinal chemistry, Aug, Volume: 54	Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
AID1223535	Drug excretion in Wistar rat urine at 750 mg/kg, po after up to 72 hrs by HPLC-UV analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223570	AUC (0.083 to 4 hrs) in Wistar rat brain at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1677632	Cytotoxicity against rat PC12D cells assessed as reduction in cell viability at 30 uM by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Effect of methoxyflavones contained in Kaempferia parviflora on CRE-mediated transcription in PC12D cells.
AID1223545	Drug excretion in Wistar rat urine at 750 mg/kg, po after 24 to 72 hrs by HPLC-UV analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID666853	Cytotoxicity against human LCC-6 cells after 5 days by MTS assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID1223569	AUC (0.083 to 4 hrs) in Wistar rat lung at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID768689	Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID596245	Effect on C/EBPdelta mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID666769	Inhibition of thrombin in New Zealand rabbit plasma assessed as prothrombin time at 100 uM by coagulometry	2012	European journal of medicinal chemistry, Aug, Volume: 54	Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
AID1223526	Tmax in Wistar rat lung at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223531	Drug excretion in Wistar rat feces at 750 mg/kg, po after 12 hrs by HPLC-UV analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596448	Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 10 uM by liquid scintillation counting (Rvb = 100.0 %)	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596460	Effect on GlUT4 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223562	Tmax in Wistar rat at 250 mg/kg, po by HPLC analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223568	AUC (0.083 to 4 hrs) in Wistar rat kidney at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223528	Tmax in Wistar rat testes at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID1223542	Drug metabolism in Wistar rat assessed as excretion of 2-(3-hydroxy-4-methoxyphenyl)-3,5,7-trimethoxy-4H-chromen-4-one in urine at 750 mg/kg, po by LC-MS and LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596471	Effect on C/EBPbeta mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596463	Effect on aP2 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID666858	Reversal of BCRP-mediated drug resistant in human MCF7-MX100 cells assessed as potentiation of topotecan-induced cytotoxicity at 1 uM after 5 days by MTS assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID596461	Effect on GlUT4 mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1871970	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay relative to control	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Quercetin derivatives: Drug design, development, and biological activities, a review.
AID596678	Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 1 uM by liquid scintillation counting (Rvb = 100.0 %)	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596675	Induction of adiponectin protein secretion in mouse 3T3L1 cells at 3 uM on day 8 by ELISA relative to control	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID220006	Relative inhibition of cAMP and cGMP hydrolysis by particulate phosphodiesterase	1982	Journal of medicinal chemistry, Oct, Volume: 25, Issue:10	Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
AID666859	Reversal of MRP1-mediated drug resistant in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity at 1 uM after 5 days by MTS assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID1223523	Cmax in Wistar rat testes at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID768684	Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID666856	Reversal of p-glycoprotein-mediated drug resistant in human LCC-6/MDR cells assessed as potentiation of paclitaxel-induced cytotoxicity at 1 uM after 5 days by MTS assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID768686	Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation at 10 uM preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay relative to control	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID404008	Cytotoxicity against human KB cells
AID1223538	AUC (0.083 to 4 hrs) in Wistar rat testes at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596459	Effect on PPARgamma2 mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596456	Effect on adiponectin mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID596458	Effect on PPARgamma2 mRNA expression in mouse 3T3L1 cells at 10 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID666854	Cytotoxicity against multidrug resistant human LCC-6 cells after 5 days by MTS assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells.
AID1871971	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	Quercetin derivatives: Drug design, development, and biological activities, a review.
AID1223520	Cmax in Wistar rat kidney at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID596465	Effect on aP2 mRNA expression in mouse 3T3L1 cells at 30 uM on day 8 by RT-PCR relative to beta-actin mRNA expression	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1223525	Tmax in Wistar rat kidney at 750 mg/kg, po by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (4.76)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (4.76)	29.6817
2010's	15 (71.43)	24.3611
2020's	4 (19.05)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (9.09%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
hydrogen sulfide Hydrogen Sulfide: A flammable, poisonous gas with a characteristic odor of rotten eggs. It is used in the manufacture of chemicals, in metallurgy, and as an analytical reagent. (From Merck Index, 11th ed). hydrogen sulfide : A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen.. thiol : An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety.	2.13	1	gas molecular entity; hydracid; mononuclear parent hydride; sulfur hydride	Escherichia coli metabolite; genotoxin; metabolite; signalling molecule; toxin; vasodilator agent
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.1	1	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
beta-naphthoflavone beta-Naphthoflavone: A polyaromatic hydrocarbon inducer of P4501A1 and P4501A2 cytochromes. (Proc Soc Exp Biol Med 1994 Dec:207(3):302-308). beta-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the f side of flavone.	2.08	1	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.07	1	aromatic ether; nitrile; polyether; tertiary amino compound
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	2.25	1
lapachol lapachol : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.	2.25	1
nalidixic acid [no description available]	2.25	1	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.	1.96	1	methoxybenzenes
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	2.06	1	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	2.52	2	catechin	antioxidant; plant metabolite
flavanone flavanone: RN given refers to cpd with unspecified isomeric designation; structure in first source. flavanone : The simplest member of the class of flavanones that consists of flavan bearing an oxo substituent at position 4.	2.06	1	flavanones
flavone flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.	2.06	1	flavones	metabolite; nematicide
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.48	2	flavonols; monohydroxyflavone
alpha-naphthoflavone alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).	2.08	1	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor
quercetin pentaacetate quercetin pentaacetate: inhibits PGE2 production and COX-2 protein expression; structure in first source	1.96	1
silybin silibinin : A flavonolignan isolated from milk thistle, Silybum marianum, that has been shown to exhibit antioxidant and antineoplastic activities.	2.25	1	aromatic ether; benzodioxine; flavonolignan; polyphenol; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; hepatoprotective agent; plant metabolite
fenoldopam mesylate [no description available]	2.25	1	benzazepine
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.25	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
epicatechin (-)-epicatechin : A catechin with (2R,3R)-configuration.	2.52	2	catechin; polyphenol	antioxidant
gallocatechol (-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration.	2.52	2	catechin; flavan-3,3',4',5,5',7-hexol	antioxidant; food component; plant metabolite
nobiletin nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.	2.06	1	methoxyflavone	antineoplastic agent; plant metabolite
narciclasine narciclasine: antitumor alkaloid from bulbs of Narcissus species	2.25	1	phenanthridines	metabolite
(-)-catechin (-)-catechin : The (-)-enantiomer of catechin.	2.25	1	catechin	metabolite
5,7,4'-trimethylapigenin 5,7,4'-trimethylapigenin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source	2.79	3	ether; flavonoids
5,7-dimethoxyflavone chrysin 5,7-dimethyl ether : A dimethoxyflavone that is the 5,7-dimethyl ether derivative of chrysin.	3.02	4	dimethoxyflavone	plant metabolite
quercetin 5,7,3',4'-tetramethyl ether quercetin 5,7,3',4'-tetramethyl ether : A tetramethoxyflavone that is the 5,7,3',4'-tetramethy-derivative of quercetin.	2.07	1	flavonols; tetramethoxyflavone	plant metabolite
homoorientin homoorientin: isolated from Swertia japonica; structure given in first source	2.25	1	flavone C-glycoside; tetrahydroxyflavone	antineoplastic agent; radical scavenger
penta-o-ethylquercetin penta-O-ethylquercetin: structure given in first source	1.96	1
3',4'-dihydroxyflavone 3',4'-dihydroxyflavone: inhibitors of arachidonic acid peroxidation	2.52	2
3-methoxyflavone 3-methoxyflavone: from Aspergillus niger; structure in first source	2.08	1
ampelopsin ampelopsin: hepatoprotective agent; isolated from Hovenia dulcis; RN given for (2R-trans)-isomer; structure in first source. (+)-dihydromyricetin : An optically active form of dihydromyricetin having (2R,3R)-configuration.	2.25	1	dihydromyricetin; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; metabolite
3',4'-dimethoxy-alpha-naphthoflavone 3',4'-dimethoxy-alpha-naphthoflavone: activated Ah receptor; structure in first source	2.08	1
taxifolin (+)-taxifolin : A taxifolin that has (2R,3R)-configuration.	2.25	1	taxifolin	metabolite
eriodictyol eriodictyol: structure. eriodictyol : A tetrahydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7, 3' and 4' respectively.	2.52	2	3'-hydroxyflavanones; tetrahydroxyflavanone
silychristin silychristin : A flavonolignan isolated from Silybum marianum and has been shown to exhibit inhibitory activities against lipoxygenase and prostaglandin synthetase.	2.25	1	1-benzofurans; aromatic ether; flavonolignan; polyphenol; secondary alpha-hydroxy ketone	lipoxygenase inhibitor; metabolite; prostaglandin antagonist; radical scavenger
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.25	1	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
5,7,3',4',5'-pentamethoxyflavone 5,7,3',4',5'-pentamethoxyflavone: antineoplastic agent that reverses P-glycoprotein-mediated multidrug resistance; structure in first source	2.25	1
5,7,3',4'-tetramethylluteolin 5,7,3',4'-tetramethylluteolin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source	2.52	2
isoliquiritigenin [no description available]	2.06	1	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
3',4',5'-trimethoxyflavonol 3',4',5'-trimethoxyflavonol: has anticarcinogenic activity; structure in first source	3.51	1
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.25	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	2.25	1	cinnamate ester; tannin	food component; plant metabolite
1,1-diphenyl-2-picrylhydrazyl 1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)	2.1	1
quercetin [no description available]	4.4	6	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
biochanin a [no description available]	2.06	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	antineoplastic agent; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
3,7-dimethoxy-5,3',4'-trihydroxyflavone 3,7-dimethoxy-5,3',4'-trihydroxyflavone: isolated from Veronia eremophila; structure given in first source. 3',4',5-trihydroxy-3,7-dimethoxyflavone : A dimethoxyflavone that the 3,7-di-O-methyl derivative of quercetin.	2.07	1	dimethoxyflavone; trihydroxyflavone	EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite
vitexin [no description available]	2.25	1	C-glycosyl compound; trihydroxyflavone	antineoplastic agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; plant metabolite; platelet aggregation inhibitor
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.52	2	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	3.96	3	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
luteolin-7-glucoside luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.25	1	beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	antioxidant; plant metabolite
gossypetin gossypetin: inhibits activity of penicillinase enzyme in E coli. gossypetin : A hexahydroxyflavone having the hydroxy groups placed at the 3-, 3'-, 4'-, 5- 7- and 8-positions.	2.06	1	7-hydroxyflavonol; hexahydroxyflavone	plant metabolite
quercetin 3-o-methyl ether quercetin 3-O-methyl ether: from Rhamnus species; structure in first source. 3',4',5,7-tetrahydroxy-3-methoxyflavone : A tetrahydroxyflavone having the 4-hydroxy groups located at the 3'- 4'- 5- and 7-positions as well as a methoxy group at the 2-position.	2.07	1	monomethoxyflavone; tetrahydroxyflavone	antimicrobial agent; metabolite
ayanin ayanin: has cytoprotective and anti-neuroinflammatory activities; isolated from Croton schiedeanus (Euphorbiaceae); structure in first source. 3',5-dihydroxy-3,4',7-trimethoxyflavone : A trimethoxyflavone that is quercetin in which the hydroxy groups at positions 3, 4' and 7 have been replaced by methoxy groups.	2.76	3	dihydroxyflavone; trimethoxyflavone	plant metabolite
quercetin 3-o-glucopyranoside quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells	3.64	2	beta-D-glucoside; monosaccharide derivative; quercetin O-glucoside; tetrahydroxyflavone	antineoplastic agent; antioxidant; antipruritic drug; bone density conservation agent; geroprotector; histamine antagonist; osteogenesis regulator; plant metabolite
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	3.65	2	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol [no description available]	2.52	2	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
genistein [no description available]	2.52	2	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
butein [no description available]	2.06	1	chalcones; polyphenol	antineoplastic agent; antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor; geroprotector; hypoglycemic agent; plant metabolite; radiosensitizing agent; tyrosine kinase inhibitor
apigenin dimethylether apigenin dimethylether: a dimethoxy analog of apigenin from roots of Rhus undulata and possibly other plants. apigenin 7,4'-dimethyl ether : A dimethoxyflavone that is the 7,4'-dimethyl ether derivative of apigenin.	2.52	2	dimethoxyflavone; monohydroxyflavone	plant metabolite
azaleatin azaleatin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 5 is replaced by a methoxy group.	2.07	1	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	plant metabolite
baicalein [no description available]	2.06	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.07	1	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
diosmetin [no description available]	2.25	1	3'-hydroxyflavonoid; monomethoxyflavone; trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; bone density conservation agent; cardioprotective agent; plant metabolite; tropomyosin-related kinase B receptor agonist; vasodilator agent
fisetin [no description available]	2.52	2	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
galangin 5,7-dihydroxyflavonol: antimicrobial from the twigs of Populus nigra x Populus deltoides; structure in first source. galangin : A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.	3.51	1	7-hydroxyflavonol; trihydroxyflavone	antimicrobial agent; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; plant metabolite
genkwanin genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.	2.07	1	dihydroxyflavone; monomethoxyflavone	metabolite
3-methylquercetin isorhamnetin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.	2.07	1	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	anticoagulant; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.25	1	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
myricetin [no description available]	2.52	2	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
myricitrin myricitrin: isolated from root bark of Myrica cerifera L.; structure. myricitrin : A glycosyloxyflavone that consists of myricetin attached to a alpha-L-rhamnopyranosyl residue at position 3 via a glycosidic linkage. Isolated from Myrica cerifera, it exhibits anti-allergic activity.	2.25	1	alpha-L-rhamnoside; glycosyloxyflavone; monosaccharide derivative; pentahydroxyflavone	anti-allergic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; plant metabolite
orientin orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer. orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.	2.25	1	3'-hydroxyflavonoid; C-glycosyl compound; tetrahydroxyflavone	antioxidant; metabolite
rhamnetin rhamnetin: aglycone of xanthorhamnin; from Rhamnus. rhamnetin : A monomethoxyflavone that is quercetin methylated at position 7.	2.47	2	monomethoxyflavone; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; metabolite
tamarixetin tamarixetin: isolated from Costsus spicatus. tamarixetin : A monomethoxyflavone that is quercetin methylated at position O-4'. Isolated from Cyperus teneriffae.	2.07	1	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	antioxidant; metabolite
tricetin tricetin : Flavone hydroxylated at positions 3', 4', 5, 5' and 7.	2.25	1	pentahydroxyflavone	antineoplastic agent; metabolite
wogonin wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.	2.06	1	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite
daidzein [no description available]	2.06	1	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
7-hydroxyflavone 7-hydroxyflavone : A hydroxyflavonoid in which the flavone nucleus is substituted at position 7 by a hydroxy group.	2.06	1	hydroxyflavonoid
tectochrysin tectochrysin: structure in first source. tectochrysin : A monohydroxyflavone that is flavone substituted by a hydroxy group at position 4 and a methoxy group at position 7 respectively.	2.79	3	monohydroxyflavone; monomethoxyflavone	antidiarrhoeal drug; antineoplastic agent; plant metabolite
4',7-dihydroxyflavone 4',7-dihydroxyflavone: inducer of nod gene. 4',7-dihydroxyflavone : A dihydroxyflavone in which the two hydroxy substituents are located at positions 4' and 7.	2.06	1	dihydroxyflavone	metabolite
astragalin kaempferol-3-O-glucoside: isolated from the pit of Mahkota dewa; structure in first source. kaempferol 3-O-beta-D-glucoside : A kaempferol O-glucoside in which a glucosyl residue is attached at position 3 of kaempferol via a beta-glycosidic linkage.	2.06	1	beta-D-glucoside; kaempferol O-glucoside; monosaccharide derivative; trihydroxyflavone	plant metabolite; trypanocidal drug
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.08	1	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
ombuine ombuine: from rhizome of Alpinia tonkinensis. ombuin : A dimethoxyflavone that is quercetin in which the hydroxy groups at positions 7 and 4' are replaced by methoxy groups. Isolated from Cyperus teneriffae, it exhibits anti-inflammatory activity.	2.76	3	dimethoxyflavone; flavonols; trihydroxyflavone	anti-inflammatory agent; plant metabolite
kaempferol-7-methyl ether rhamnocitrin : A monomethoxyflavone that is the 7-methyl ether derivative of kaempferol.	2.07	1	flavonols; monomethoxyflavone; trihydroxyflavone	plant metabolite
thunberginol a thunberginol A: isolated from Hydrangeae dulcis folium; structure given in first source	2.25	1
5,7,2'-trihydroxyflavone 5,7,2'-trihydroxyflavone: has inhibitory effects on the EBV-EA activation & on mouse skin tumor promotion in an in vivo two-stage carcinogenesis test; from Scutellaria baicalensis; structure given in first source	2.25	1	flavones
3',4',7-trihydroxyflavone 3',4',7-trihydroxyflavone: from the Sudanese medicinal plant Albizia zygia; structure in first source	2.06	1	flavones
5-hydroxy-3,3',4',7-tetramethoxyflavone 5-hydroxy-3,7,3',4'-tetramethoxyflavone: from the rhizome of Kaempferia parviflora; inhibits monocyte adhesion and cellular reactive oxygen species production in human umbilical vein endothelial cells. 5-hydroxy-3,3',4',7-tetramethoxyflavone : A monohydroxyflavone that is 5-hydroxyflavone which is substituted by methoxy groups at positions 3,3',4' and 7.	3.49	7	3'-methoxyflavones; monohydroxyflavone; tetramethoxyflavone	plant metabolite
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid: chromogen in glucose oxidase-peroxidase method for determining serum glucose; used in free radical scavenging assays; structure in first source	2.1	1
guajavarin guajavarin: from leaves of Psidium guajava	2.25	1
3,7-dimethylgalangin 3,7-dimethylgalangin: from the resinous exudate of Heliotropium huascoense; structure in first source	2.79	3
ko 143 [no description available]	2.48	2	beta-carbolines; tert-butyl ester
zaprinast zaprinast: anaphylaxis inhibitor; structure	1.96	1	triazolopyrimidines
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.11	1	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Benign Neoplasms [description not available]	3.03	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.03	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	2.1	1
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	2.07	1

3,5,7,3',4'-pentamethoxyflavone

Description

Cross-References

Synonyms (73)

Research Excerpts

Pharmacokinetics

Bioavailability

Protein Targets (38)

Potency Measurements

Inhibition Measurements

Biological Processes (39)

Molecular Functions (27)

Ceullar Components (14)

Bioassays (121)

Research

Studies (21)

Market Indicators

Research Demand Index: 11.77

Study Types

3,5,7,3',4'-pentamethoxyflavone

Description

Cross-References

Synonyms (73)

Research Excerpts

Pharmacokinetics

Bioavailability

Protein Targets (38)

Potency Measurements

Inhibition Measurements

Biological Processes (39)

Molecular Functions (27)

Ceullar Components (14)

Bioassays (121)

Research

Studies (21)

Market Indicators

Research Demand Index: 11.77

Study Types

Related Drugs (93)

Related Conditions (8)